Head and Neck Oncology

Annals of Surgical Oncology

, Volume 18, Issue 9, pp 2564-2568

Inoperable Symptomatic Recurrent Thyroid Cancers: Preliminary Result of Radiofrequency Ablation

  • Ko Woon ParkAffiliated withDepartment of Radiology and Center for Imaging Science, Samsung Medical Center, Sungkyunkwan University School of Medicine
  • , Jung Hee ShinAffiliated withDepartment of Radiology and Center for Imaging Science, Samsung Medical Center, Sungkyunkwan University School of Medicine Email author 
  • , Boo-Kyung HanAffiliated withDepartment of Radiology and Center for Imaging Science, Samsung Medical Center, Sungkyunkwan University School of Medicine
  • , Eun Young KoAffiliated withDepartment of Radiology and Center for Imaging Science, Samsung Medical Center, Sungkyunkwan University School of Medicine
  • , Jae Hoon ChungAffiliated withDepartment of Internal Medicine, Division of Endocrinology and Metabolism, Samsung Medical Center, Sungkyunkwan University School of Medicine

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access

Purpose

To determine the role of radiofrequency ablation (RFA) in patients with inoperable symptomatic recurrent thyroid cancers.

Materials and Methods

Eleven patients with 16 symptomatic recurrent thyroid cancers but ineligible for surgery were prospectively enrolled and underwent ultrasound-guided RFA with local anesthesia in 16 sessions. The mean tumor volume and diameter were 9 ml (range 0.1–34 ml) and 2.9 cm (range 0.7–4.8 cm), respectively. Patients had dysphagia, hoarseness, dyspnea, or a protruding mass due to recurrent tumors. Tumor volume was calculated from follow-up ultrasound, and symptoms were assessed after RFA.

Results

Of 16 sessions, tumor ablation was complete in 6, incomplete in 9, and failed in 1. Incomplete or failed ablation was due to intolerable pain, severe calcified lesion, or tumor encasement of major vessels. Of 15 treated lesions, 13 decreased in volume. Regrowth of treated tumors was observed in 2 lesions. The mean volume reduction was 50.9% (range −9.4 to 96.8%). There were gains for symptom relief for 7 patients (63.6%) with protruding masses (n = 6) and discomfort due to tracheal compression (n = 1). The mean follow-up was 6 months (1–14 months). There were no major complications except a patient with skin burn.

Conclusion

RFA is feasible and safe, and can improve symptoms in the short term.